antibody

FGF23 (Fibroblast Growth Factor 23)

MBS438036

0.02 mg (With BSA & Azide at 0.2 mg/ml)

190 USD

monoclonal

mouse

nonconjugated

[FGF23/638]

ELISA, enzyme immunoassay

Antibody

FGF23 (Fibroblast Growth Factor 23)

[FGF23]

[ADHR; FGF-23; FGFN; Fibroblast growth factor 23; HPDR2; HYPF; Phosphatonin; PHPTC; Tumor-derived hypophosphatemia-inducing factor]

[fibroblast growth factor 23; Fibroblast growth factor 23; fibroblast growth factor 23; phosphatonin; tumor-derived hypophosphatemia inducing factor; fibroblast growth factor 23; Phosphatonin; Tumor-derived hypophosphatemia-inducing factorCleaved into the following 2 chains:Fibroblast growth factor 23 N-terminal peptide; Fibroblast growth factor 23 C-terminal peptide]

[FGF23]

[FGF23; FGF23; ADHR; FGFN; HYPF; HPDR2; PHPTC; HYPF; FGF-23]

FGF23_HUMAN

Monoclonal

IgG1, kappa

[FGF23/638]

Mouse

Human. Others not known.

251

Fibroblast growth factor-1 (FGF-1), also designated acidic FGF, and fibroblast growth factor-2 (FGF-2), also designated basic FGF, are members of a family of growth factors that stimulate proliferation of cells of mesenchymal, epithelial and neuroectodermal origin. Additional members of the FGF family include the oncogenes FGF-3 (Int2) and FGF-4 (hst/Kaposi), FGF-5, FGF-6, FGF-7 (KGF), FGF-8 (AIGF), FGF-9 (GAF) and FGF-10 through FGF-23. Members of the FGF family share 30-55% amino acid sequence identity and similar gene structure, and are capable of transforming cultured cells when overexpressed in trans- fected cells. Cellular receptors for FGFs are members of a second multigene family, including four tyrosine kinases designated Flg (FGFR-1), Bek (FGFR-L), TKF and FGFR-3.

200 ug/ml of Ab purified from Bioreactor Concnetrate by Protein A/G. Prepared in 10 mM PBS with 0.05% BSA & 0.05% azide.

Antibody with azide store at 2-8°C. Antibody is stable fot 24 months. Non hazardous. No MSDS required.

ELISA (EIA), Functional Studies

ELISA (For coating, order Ab without BSA); Functional Studies (Order Ab without BSA Optimal dilution for a specific application should be determined.

Localization: Secreted (extracellular). Positive Control: Human PBL cells or brain tumors. Human Chromosomal Location: 12p13.32

Immunogen: Recombinant human FGF23 protein. Quantity and Buffer: 0.5 ml at 200ug/ml with BSA and azide

1. Yamashita, T., et al. 2000. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem. Biophys. Res. Commun. 277: 494-498.

10190674

NP_065689.1

NM_020638.2

Q9GZV9

12-32kDa

Activated Point Mutants Of FGFR2 Pathway (645281); Adaptive Immune System Pathway (366160); Constitutive PI3K/AKT Signaling In Cancer Pathway (685535); DAP12 Interactions Pathway (685549); DAP12 Signaling Pathway (685550); Disease Pathway (530764); Downstream Signal Transduction Pathway (106385); Downstream Signaling Events Of B Cell Receptor (BCR) Pathway (576250); Downstream Signaling Of Activated FGFR Pathway (160957); FGF Signaling Pathway (137989)

This gene encodes a member of the fibroblast growth factor family of proteins, which possess broad mitogenic and cell survival activities and are involved in a variety of biological processes. The product of this gene regulates phosphate homeostasis and transport in the kidney. The full-length, functional protein may be deactivated via cleavage into N-terminal and C-terminal chains. Mutation of this cleavage site causes autosomal dominant hypophosphatemic rickets (ADHR). Mutations in this gene are also associated with hyperphosphatemic familial tumoral calcinosis (HFTC). [provided by RefSeq, Feb 2013]

FGF23: Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Upregulates EGR1 expression in the presence of KL. Acts directly on the parathyroid to decrease PTH secretion. Regulator of vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralization. Defects in FGF23 are the cause of autosomal dominant hypophosphataemic rickets (ADHR). ADHR is characterized by low serum phosphorus concentrations, rickets, osteomalacia, leg deformities, short stature, bone pain and dental abscesses. Defects in FGF23 are a cause of hyperphosphatemic familial tumoral calcinosis (HFTC). HFTC is a severe autosomal recessive metabolic disorder that manifests with hyperphosphatemia and massive calcium deposits in the skin and subcutaneous tissues. Belongs to the heparin-binding growth factors family. Protein type: Secreted; Cytokine; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 12p13.3. Cellular Component: extracellular space; extracellular region. Molecular Function: growth factor activity; type 1 fibroblast growth factor receptor binding. Biological Process: epidermal growth factor receptor signaling pathway; phosphoinositide-mediated signaling; fibroblast growth factor receptor signaling pathway; nerve growth factor receptor signaling pathway; positive regulation of transcription, DNA-dependent; negative regulation of hormone secretion; phosphate metabolic process; negative regulation of bone mineralization; cellular phosphate ion homeostasis; insulin receptor signaling pathway; innate immune response; negative regulation of osteoblast differentiation; phosphate ion homeostasis; cell differentiation; vitamin D catabolic process. Disease: Hypophosphatemic Rickets, Autosomal Dominant

0.02 mg (With BSA & Azide at 0.2 mg/ml)

190 USD

0.1 mg (With BSA & Azide at 0.2mg/ml)

340

0.1 mg (Without BSA & Azide at 1mg/ml)

340